Journal of Virology publishes paper on Rational Vaccines live-attenuated vaccine candidate
The major finding of the study, "Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice," found that the company's RVX101 vaccine candidate used to immunize a unique mouse line (does not generate much of a neutralizing antibody response to the virus) was shown to provide highly protective immunity and prevent herpes-associated neovascularization. This robust efficacy was found to be correlated with CD8+ T cells, since depleting these cells after vaccinati...